GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34+hematopoietic progenitor cells in patients ≥60 and

(2013) Ivana N. Micallef et al.   AMERICAN JOURNAL OF HEMATOLOGY

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

(2013) I. Ben-Batalla et al.   BLOOD

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

(2013) I.-K. Park et al.   BLOOD

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

(2013) A B Lee-Sherick et al.   ONCOGENE

Meta-Analysis of Microarray Data IdentifiesGAS6Expression as an Independent Predictor of Poor Survival in Ovarian Cancer

(2013) Michelle Buehler et al.   Biomed Research International

An Infernal Trio: The chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology

(2012) Kirsten Hattermann et al.   ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

(2012) G. L. Uy et al.   BLOOD

Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation

(2012) Rosa M. Suárez et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Age-Related Prognostic Impact of Different Types ofDNMT3AMutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

(2012) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

RUNX1Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

(2012) Jason H. Mendler et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

(2012) Eyal C. Attar et al.   JOURNAL OF CLINICAL ONCOLOGY

Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2

(2012) Ling Jiang et al.   TUMOR BIOLOGY

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

(2011) K. H. Metzeler et al.   BLOOD

Macrophage–tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands

(2011) Thomas Schmidt et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

TET2Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2011) Klaus H. Metzeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

(2011) M R Baer et al.   LEUKEMIA

Targeting Axl and Mer Kinases in Cancer

(2011) A. Verma et al.   MOLECULAR CANCER THERAPEUTICS

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

(2010) J. E. Kolitz et al.   BLOOD

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) S. Schwind et al.   BLOOD

AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer

(2010) E. B. Rankin et al.   CANCER RESEARCH

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

(2010) X Ye et al.   ONCOGENE

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

(2009) I. Cristobal et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3

(2009) Kristina Masson et al.   CELLULAR SIGNALLING

Prognostic Importance ofMN1Transcript Levels, and Biologic Insights FromMN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2009) Christian Langer et al.   JOURNAL OF CLINICAL ONCOLOGY

Favorable Prognostic Impact ofNPM1Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

(2009) Heiko Becker et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical implications of c-Kit mutations in acute myelogenous leukemia

(2009) Muriel Malaise et al.   Current Hematologic Malignancy Reports

Axl and Growth Arrest Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme

(2008) M. Hutterer et al.   CLINICAL CANCER RESEARCH

KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: Two novel mutations and selective occurrence in leukemia subtypes and age groups

(2008) Narongrit Sritana et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2008) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With,CEBPAMutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

(2008) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

(2008) Maria R. Baer et al.   JOURNAL OF CLINICAL ONCOLOGY